A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 27, 2010

Primary Completion Date

May 5, 2011

Study Completion Date

January 27, 2012

Conditions

Worsening Chronic Heart FailureChronic Kidney Disease

Interventions

DRUG

Finerenone (BAY94-8862)

10 mg BAY94-8862 immediate release (IR) tablet, administered orally

Trial Locations (1)

Kiel